SPCC (Sharing Progress in Cancer Care) shared a post on LinkedIn:
“Is MRD the ultimate game-changer in Multiple Myeloma management?
MRD has evolved from a research curiosity to a pivotal endpoint in clinical trials and a cornerstone of personalised therapy. But how do we bridge the gap between foundations and daily clinical relevance?
To answer this, we have gathered the world’s leading experts:
- Jesús San-Miguel, ES
- Carl Ola Landgren, US
- Bruno Paiva, ES
- Jill Corre, FR
- Luciano Costa, US
- Elena Zamagni, IT
They will discuss:
- Understanding MRD in multiple myeloma: from the early days into the current role as an early endpoint in clinical trials
- Prognostic value of MRD
- MRD detection technologies
Wednesday, 11 February 2026, 18:00 CET
Register.
This activity is supported by an unrestricted medical contribution from Sanofi. Procedures for further independent support are ongoing.”
More posts featuring SPCC.